Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

Leuven, BELGIUM, Boston, MA, US– November 20, 2023– 7:00 am CET– Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company announced today that topline data in its KALAHARI Phase 2, Part B clinical trial for diabetic...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials